# Melanotans

Sonoran UV Biology · Clinical & Regulatory Field Report

**Directory:** [Tucson Origin](/tucson-origin) · [Five Receptors](/five-receptors) · [Scenesse](/afamelanotide-scenesse) · [Vyleesi](/bremelanotide-vyleesi) · [Imcivree](/setmelanotide-imcivree) · [Online Market](/melanotan-online-market) · [Case Reports](/case-reports-and-safety) · [Regulators](/regulatory-warnings) · [References](/references) · [About](/about)

**Source Ledger · 54 Research Papers, Reviews, and Official Agency Records** · Verified Final URLs

---

[Melanotans](/) / References

# Source archive for Melanotans

Every claim, receptor measurement, clinical outcome, laboratory assay, and regulatory quotation across this site traces to one of the 54 research papers, reviews, and official agency records cataloged below.

**Bibliography sections:** [I. Discovery & Receptor Biology (16)](#i-discovery--receptor-biology) · [II. Prescription Medicines & Trials (14)](#ii-prescription-medicines--pivotal-clinical-trials) · [III. Lab Assays & Case Reports (17)](#iii-online-lab-assays--clinical-case-reports) · [IV. Regulatory Warnings & Compounding (7)](#iv-regulatory-warnings--compounding)

## I. Discovery & Receptor Biology
16 sources

1. **4-Norleucine, 7-D-phenylalanine-alpha-melanocyte-stimulating hormone: a highly potent alpha-melanotropin with ultralong biological activity**
   Sawyer TK, Sanfilippo PJ, Hruby VJ, Engel MH, Heward CB, Burnett JB, Hadley ME · *Proceedings of the National Academy of Sciences of the United States of America (PNAS)*, 1980
   [https://pubmed.ncbi.nlm.nih.gov/6777774/](https://pubmed.ncbi.nlm.nih.gov/6777774/)
2. **Potent and prolonged acting cyclic lactam analogues of alpha-melanotropin: design based on molecular dynamics**
   Al-Obeidi F, Castrucci AM, Hadley ME, Hruby VJ · *Journal of Medicinal Chemistry*, 1989
   [https://pubmed.ncbi.nlm.nih.gov/2555512/](https://pubmed.ncbi.nlm.nih.gov/2555512/)
3. **Induction of skin tanning by subcutaneous administration of a potent synthetic melanotropin**
   Levine N, Sheftel SN, Eytan T, Dorr RT, Hadley ME, Weinrach JC, Ertl GA, Toth K, McGee DL, Hruby VJ · *JAMA*, 1991
   [https://pubmed.ncbi.nlm.nih.gov/1658407/](https://pubmed.ncbi.nlm.nih.gov/1658407/)
4. **The cloning of a family of genes that encode the melanocortin receptors**
   Mountjoy KG, Robbins LS, Mortrud MT, Cone RD · *Science*, 1992
   [https://pubmed.ncbi.nlm.nih.gov/1325670/](https://pubmed.ncbi.nlm.nih.gov/1325670/)
5. **Variants of the melanocyte-stimulating hormone receptor gene are associated with red hair and fair skin in humans**
   Valverde P, Healy E, Jackson I, Rees JL, Thody AJ · *Nature Genetics*, 1995
   [https://pubmed.ncbi.nlm.nih.gov/7581459/](https://pubmed.ncbi.nlm.nih.gov/7581459/)
6. **Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study**
   Dorr RT, Lines R, Levine N, Brooks C, Xiang L, Hruby VJ, Hadley ME · *Life Sciences*, 1996
   [https://pubmed.ncbi.nlm.nih.gov/8637402/](https://pubmed.ncbi.nlm.nih.gov/8637402/)
7. **Targeted disruption of the melanocortin-4 receptor results in obesity in mice**
   Huszar D, Lynch CA, Fairchild-Huntress V, Dunmore JH, Fang Q, Berkemeier LR, Gu W, Kesterson RA, Boston BA, Cone RD, Smith FJ, Campfield LA, Burn P, Lee F · *Cell*, 1997
   [https://pubmed.ncbi.nlm.nih.gov/9019399/](https://pubmed.ncbi.nlm.nih.gov/9019399/)
8. **Severe early-onset obesity, adrenal insufficiency and red hair pigmentation caused by POMC mutations in humans**
   Krude H, Biebermann H, Luck W, Horn R, Brabant G, Grüters A · *Nature Genetics*, 1998
   [https://pubmed.ncbi.nlm.nih.gov/9620771/](https://pubmed.ncbi.nlm.nih.gov/9620771/)
9. **Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-blind, placebo controlled crossover study**
   Wessells H, Fuciarelli K, Hansen J, Hadley ME, Hruby VJ, Dorr R, Levine N · *The Journal of Urology*, 1998
   [https://pubmed.ncbi.nlm.nih.gov/9679884/](https://pubmed.ncbi.nlm.nih.gov/9679884/)
10. **PT-141: a melanocortin agonist for the treatment of sexual dysfunction**
    Molinoff PB, Shadiack AM, Earle D, Diamond LE, Quon CY · *Annals of the New York Academy of Sciences*, 2003
    [https://pubmed.ncbi.nlm.nih.gov/12851303/](https://pubmed.ncbi.nlm.nih.gov/12851303/)
11. **Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization**
    Hadley ME, Dorr RT · *Peptides*, 2006
    [https://pubmed.ncbi.nlm.nih.gov/16412534/](https://pubmed.ncbi.nlm.nih.gov/16412534/)
12. **Central role of p53 in the suntan response and pathologic hyperpigmentation**
    Cui R, Widlund HR, Feige E, Lin JY, Wilensky DL, Igras VE, D'Orazio J, Fung CY, Schanbacher CF, Granter SR, Fisher DE · *Cell*, 2007
    [https://pubmed.ncbi.nlm.nih.gov/17350573/](https://pubmed.ncbi.nlm.nih.gov/17350573/)
13. **Melanocortin Receptors, Melanotropic Peptides and Penile Erection**
    King SH, Mayorov AV, Balse-Srinivasan P, Hruby VJ, Vanderah TW, Wessells H · *Current Topics in Medicinal Chemistry (via PMC)*, 2007
    [https://pmc.ncbi.nlm.nih.gov/articles/PMC2694735/](https://pmc.ncbi.nlm.nih.gov/articles/PMC2694735/)
14. **Structure, function and regulation of the melanocortin receptors**
    Yang Y · *European Journal of Pharmacology (via PMC)*, 2011
    [https://pmc.ncbi.nlm.nih.gov/articles/PMC3095696/](https://pmc.ncbi.nlm.nih.gov/articles/PMC3095696/)
15. **The Melanocortin Receptor System: A Target for Multiple Degenerative Diseases**
    Cai M, Hruby VJ · *Current Protein & Peptide Science*, 2016
    [https://pubmed.ncbi.nlm.nih.gov/26916163/](https://pubmed.ncbi.nlm.nih.gov/26916163/)
16. **Ligands for Melanocortin Receptors: Beyond Melanocyte-Stimulating Hormones and Adrenocorticotropin**
    Yuan XC, Tao YX · *Biomolecules (via PMC)*, 2022
    [https://pmc.ncbi.nlm.nih.gov/articles/PMC9599618/](https://pmc.ncbi.nlm.nih.gov/articles/PMC9599618/)

## II. Prescription Medicines & Pivotal Clinical Trials
14 sources

1. **Afamelanotide for Erythropoietic Protoporphyria**
   Langendonk JG, Balwani M, Anderson KE, Bonkovsky HL, Anstey AV, Bissell DM, Bloomer J, Edwards C, Neumann NJ, Parker C, Phillips JD, Lim HW, Hamzavi I, Deybach JC, Kauppinen R, Rhodes LE, Frank J, Murphy GM, Karstens FPJ, Sijbrands EJG, de Rooij FWM, Lebwohl M, Naik H, Goding CR, Wilson JHP, Desnick RJ · *The New England Journal of Medicine (via PMC)*, 2015
   [https://pmc.ncbi.nlm.nih.gov/articles/PMC4780255/](https://pmc.ncbi.nlm.nih.gov/articles/PMC4780255/)
2. **Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials**
   Kingsberg SA, Clayton AH, Portman D, Williams LA, Krop J, Jordan R, Lucas J, Simon JA · *Obstetrics & Gynecology*, 2019
   [https://pubmed.ncbi.nlm.nih.gov/31599840/](https://pubmed.ncbi.nlm.nih.gov/31599840/)
3. **SCENESSE (afamelanotide) implant, for subcutaneous use — Prescribing Information**
   U.S. Food and Drug Administration (FDA) · *U.S. Food and Drug Administration*, 2019
   [https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210797s000lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210797s000lbl.pdf)
4. **Orphan Drug Designations and Approvals: Afamelanotide (SCENESSE)**
   U.S. Food and Drug Administration (FDA), Office of Orphan Products Development · *U.S. Food and Drug Administration*, 2019
   [https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=263208](https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=263208)
5. **VYLEESI (bremelanotide injection), for subcutaneous use — Prescribing Information**
   U.S. Food and Drug Administration (FDA) · *U.S. Food and Drug Administration*, 2019
   [https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf)
6. **NDA 210557 Approval Letter: Vyleesi (bremelanotide) subcutaneous injection**
   U.S. Food and Drug Administration (FDA), Center for Drug Evaluation and Research · *U.S. Food and Drug Administration*, 2019
   [https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/210557Orig1s000ltr.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/210557Orig1s000ltr.pdf)
7. **Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials**
   Clément K, van den Akker E, Argente J, Bahm A, Chung WK, Connors H, De Waele K, Farooqi IS, Gonneau-Lejeune J, Gordon G, Kohlsdorf K, Poitou C, Puder L, Swain J, Stewart M, Yuan G, Wabitsch M, Kühnen P; Setmelanotide POMC and LEPR Phase 3 Trial Investigators · *The Lancet Diabetes & Endocrinology*, 2020
   [https://pubmed.ncbi.nlm.nih.gov/33137293/](https://pubmed.ncbi.nlm.nih.gov/33137293/)
8. **Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, in patients with Bardet-Biedl syndrome and Alström syndrome: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial with an open-label period**
   Haqq AM, Chung WK, Dollfus H, Haws RM, Martos-Moreno GÁ, Poitou C, Yanovski JA, Mittleman RS, Yuan G, Forsythe E, Clément K, Argente J · *The Lancet Diabetes & Endocrinology*, 2022
   [https://pubmed.ncbi.nlm.nih.gov/36356613/](https://pubmed.ncbi.nlm.nih.gov/36356613/)
9. **IMCIVREE (setmelanotide) injection, for subcutaneous use — Prescribing Information (Revised 12/2024)**
   U.S. Food and Drug Administration (FDA) · *U.S. Food and Drug Administration*, 2024
   [https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/213793s007lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/213793s007lbl.pdf)
10. **An overview of benefits and risks of chronic melanocortin-1 receptor activation**
    Böhm M, Robert C, Malhotra S, Clément K, Farooqi S · *Journal of the European Academy of Dermatology and Venereology (via PMC)*, 2025
    [https://pmc.ncbi.nlm.nih.gov/articles/PMC11664455/](https://pmc.ncbi.nlm.nih.gov/articles/PMC11664455/)
11. **IMCIVREE (setmelanotide) injection, for subcutaneous use — Prescribing Information (Revised 03/2026)**
    U.S. Food and Drug Administration (FDA) · *U.S. Food and Drug Administration*, 2026
    [https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/213793s009lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/213793s009lbl.pdf)
12. **Setmelanotide for the Treatment of Acquired Hypothalamic Obesity**
    Miller JL, van Santen HM, Phillips SA, Hamilton J, Aberle J, Sathyapalan T, Mohamed Z, McCormack SE, Shoemaker AH, Kelsey MM, Ghalib L, Stalla G, Thaker VV, Habiby R, Ode KL, Wabitsch M, Dattani M, Abuzzahab MJ, Abdullatif H, Morgan R, Stefater-Richards M, Aroda VR, Friedrich C, Han JC, Ono H, Nagasaki K, Tanaka T, Isojima T, Arima H, Scimia C, Yuan G, Müller HL, Roth CL; TRANSCEND Trial Group · *The New England Journal of Medicine*, 2026
    [https://pubmed.ncbi.nlm.nih.gov/42418774/](https://pubmed.ncbi.nlm.nih.gov/42418774/)
13. **Scenesse (afamelanotide) — European Public Assessment Report (EPAR)**
    European Medicines Agency (EMA) · *European Medicines Agency (Product information last updated 07/10/2026)*, 2026
    [https://www.ema.europa.eu/en/medicines/human/EPAR/scenesse](https://www.ema.europa.eu/en/medicines/human/EPAR/scenesse)
14. **Imcivree (setmelanotide) — European Public Assessment Report (EPAR)**
    European Medicines Agency (EMA) · *European Medicines Agency (Last updated 27/05/2026)*, 2026
    [https://www.ema.europa.eu/en/medicines/human/EPAR/imcivree](https://www.ema.europa.eu/en/medicines/human/EPAR/imcivree)

## III. Online Lab Assays & Clinical Case Reports
17 sources

1. **Melanotropic peptides: more than just 'Barbie drugs' and 'sun-tan jabs'?**
   Langan EA, Nie Z, Rhodes LE · *British Journal of Dermatology*, 2010
   [https://pubmed.ncbi.nlm.nih.gov/20545686/](https://pubmed.ncbi.nlm.nih.gov/20545686/)
2. **Melanotan II injection resulting in systemic toxicity and rhabdomyolysis**
   Nelson ME, Bryant SM, Aks SE · *Clinical Toxicology*, 2012
   [https://pubmed.ncbi.nlm.nih.gov/23121206/](https://pubmed.ncbi.nlm.nih.gov/23121206/)
3. **Melanotan and the posterior reversible encephalopathy syndrome**
   Kaski D, Stafford N, Mehta A, Jenkins IH, Malhotra P · *Annals of Internal Medicine*, 2013
   [https://pubmed.ncbi.nlm.nih.gov/23648958/](https://pubmed.ncbi.nlm.nih.gov/23648958/)
4. **Melanoma associated with the use of melanotan-II**
   Hjuler KF, Lorentzen HF · *Dermatology*, 2014
   [https://pubmed.ncbi.nlm.nih.gov/24355990/](https://pubmed.ncbi.nlm.nih.gov/24355990/)
5. **Microbiological contamination in counterfeit and unapproved drugs**
   Pullirsch D, Bellemare J, Hackl A, Trottier YL, Mayrhofer A, Schindl H, Taillon C, Gartner C, Hottowy B, Beck G, Gagnon J · *BMC Pharmacology and Toxicology (via PMC)*, 2014
   [https://pmc.ncbi.nlm.nih.gov/articles/PMC4088308/](https://pmc.ncbi.nlm.nih.gov/articles/PMC4088308/)
6. **Identification and characterization by LC-UV-MS/MS of melanotan II skin-tanning products sold illegally on the Internet**
   Breindahl T, Evans-Brown M, Hindersson P, McVeigh J, Bellis M, Stensballe A, Kimergård A · *Drug Testing and Analysis*, 2015
   [https://pubmed.ncbi.nlm.nih.gov/24771717/](https://pubmed.ncbi.nlm.nih.gov/24771717/)
7. **Risks of unregulated use of alpha-melanocyte-stimulating hormone analogues: a review**
   Habbema L, Halk AB, Neumann M, Bergman W · *International Journal of Dermatology*, 2017
   [https://pubmed.ncbi.nlm.nih.gov/28266027/](https://pubmed.ncbi.nlm.nih.gov/28266027/)
8. **Are injectable illegal polypeptide drugs safe? Case report demonstrating the presence of haemolytic Bacillus cereus in 2 illegal peptide drugs**
   Janvier S, Wattijn E, Botteldoorn N, De Spiegeleer B, Deconinck E, Vanhee C · *Drug Testing and Analysis*, 2018
   [https://pubmed.ncbi.nlm.nih.gov/28941153/](https://pubmed.ncbi.nlm.nih.gov/28941153/)
9. **Impurity profiling of the most frequently encountered falsified polypeptide drugs on the Belgian market**
   Janvier S, Cheyns K, Canfyn M, Goscinny S, De Spiegeleer B, Vanhee C, Deconinck E · *Talanta*, 2018
   [https://pubmed.ncbi.nlm.nih.gov/30029448/](https://pubmed.ncbi.nlm.nih.gov/30029448/)
10. **Falsification of biotechnology drugs: current dangers and/or future disasters?**
    Janvier S, De Spiegeleer B, Vanhee C, Deconinck E · *Journal of Pharmaceutical and Biomedical Analysis*, 2018
    [https://pubmed.ncbi.nlm.nih.gov/30165334/](https://pubmed.ncbi.nlm.nih.gov/30165334/)
11. **Melanotan-induced priapism: a hard-earned tan**
    Dreyer BA, Amer T, Fraser M · *BMJ Case Reports*, 2019
    [https://pubmed.ncbi.nlm.nih.gov/30796078/](https://pubmed.ncbi.nlm.nih.gov/30796078/)
12. **Melanotan II: a possible cause of renal infarction: review of the literature and case report**
    Peters B, Hadimeri H, Wahlberg R, Afghahi H · *CEN Case Reports*, 2020
    [https://pubmed.ncbi.nlm.nih.gov/31953620/](https://pubmed.ncbi.nlm.nih.gov/31953620/)
13. **Melanotan Tanning Injection: A Rare Cause of Priapism**
    Mallory CW, Lopategui DM, Cordon BH · *Sexual Medicine (via PMC)*, 2021
    [https://pmc.ncbi.nlm.nih.gov/articles/PMC7930850/](https://pmc.ncbi.nlm.nih.gov/articles/PMC7930850/)
14. **Melanotan II User Experience: A Qualitative Study of Online Discussion Forums**
    Gilhooley E, Daly S, McKenna D · *Dermatology*, 2021
    [https://pubmed.ncbi.nlm.nih.gov/34464955/](https://pubmed.ncbi.nlm.nih.gov/34464955/)
15. **Changes in Oral Mucosa Associated with Melanotan II Injections: A Case Report**
    Bonchev A · *Life (via PMC)*, 2026
    [https://pmc.ncbi.nlm.nih.gov/articles/PMC12942211/](https://pmc.ncbi.nlm.nih.gov/articles/PMC12942211/)
16. **Insights into Tanning Biology and Tanning Products**
    Resnick G, Khajeh-Afzaly M, Yousefian F, Raza A, Issa NT · *The Journal of Clinical and Aesthetic Dermatology*, 2026
    [https://pubmed.ncbi.nlm.nih.gov/41890775/](https://pubmed.ncbi.nlm.nih.gov/41890775/)
17. **Five primary melanomas in situ in a patient with recent tanning bed use, melanotan exposure, and anabolic hormone use**
    Vadner DJ, Smith S · *JAAD Case Reports (via PMC)*, 2026
    [https://pmc.ncbi.nlm.nih.gov/articles/PMC13279914/](https://pmc.ncbi.nlm.nih.gov/articles/PMC13279914/)

## IV. Regulatory Warnings & Compounding
7 sources

1. **Warning against the tanning product Melanotan**
   Danish Medicines Agency · *Danish Medicines Agency (Lægemiddelstyrelsen, 20 June 2011)*, 2011
   [https://laegemiddelstyrelsen.dk/en/pharmacies/medicines-imported-from-abroad/warnings-against-products/warning-against-the-tanning-product-melanotan/](https://laegemiddelstyrelsen.dk/en/pharmacies/medicines-imported-from-abroad/warnings-against-products/warning-against-the-tanning-product-melanotan/)
2. **FOI 24/274 – Side effects reports of melanotan II products**
   Medicines and Healthcare products Regulatory Agency (MHRA) · *UK Medicines and Healthcare products Regulatory Agency (17 April 2024)*, 2024
   [https://assets.publishing.service.gov.uk/media/669fbd3aa3c2a28abb50d55a/Final_Redaction_FOI_24_274.pdf](https://assets.publishing.service.gov.uk/media/669fbd3aa3c2a28abb50d55a/Final_Redaction_FOI_24_274.pdf)
3. **Don’t risk using tanning products containing melanotan**
   Therapeutic Goods Administration (TGA) · *Australian Government, Therapeutic Goods Administration (24 January 2025)*, 2025
   [https://www.tga.gov.au/news/blog/dont-risk-using-tanning-products-containing-melanotan](https://www.tga.gov.au/news/blog/dont-risk-using-tanning-products-containing-melanotan)
4. **Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks**
   U.S. Food and Drug Administration (FDA) · *U.S. Food and Drug Administration (Content current as of 04/22/2026)*, 2026
   [https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks](https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks)
5. **Consumer advisory: Unapproved peptide products health warning**
   Medsafe (New Zealand Medicines and Medical Devices Safety Authority) · *Medsafe New Zealand (21 May 2026)*, 2026
   [https://www.medsafe.govt.nz/safety/Alerts/Consumer-advisory-Unapproved-peptide-products-health-warning.asp](https://www.medsafe.govt.nz/safety/Alerts/Consumer-advisory-Unapproved-peptide-products-health-warning.asp)
6. **Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (91 FR 68526)**
   Office of the Secretary, U.S. Department of Health and Human Services (HHS) · *Federal Register (October 30, 2026)*, 2026
   [https://www.federalregister.gov/documents/2026/10/30/2026-22192/enforcement-discretion-policy-regarding-503a-compounding-using-certain-peptide-bulk-drug-substances](https://www.federalregister.gov/documents/2026/10/30/2026-22192/enforcement-discretion-policy-regarding-503a-compounding-using-certain-peptide-bulk-drug-substances)
7. **HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (Draft Policy Text and Appendices A & B)**
   U.S. Department of Health and Human Services (HHS) · *U.S. Department of Health and Human Services (announced October 30, 2026 via 91 FR 68526)*, 2026
   [https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf](https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf)

---

## Archive Audit · 54 Sources

- **Total Sources:** 54 distinct opened documents (1980–2026)
- **Source Categories:** 16 discovery & receptor papers · 14 prescription-medicine labels, EPARs & trials · 17 lab assays & clinical cases · 7 regulatory warnings & compounding texts
- **Verification Rule:** Every cited URL resolves directly to PubMed, PMC, FDA, EMA, Federal Register, HHS, UK MHRA, Australia TGA, New Zealand Medsafe, or Denmark DKMA
- **Excluded Sources:** Zero vendor blogs, zero forum claims treated as medical evidence, zero secondary content farms, zero redirect links

### Read by Dispatch
- [01. Tucson Origin (1916–2026)](/tucson-origin)
- [02. Five Receptors Biology](/five-receptors)
- [03. Afamelanotide (Scenesse)](/afamelanotide-scenesse)
- [04. Bremelanotide (Vyleesi)](/bremelanotide-vyleesi)
- [05. Setmelanotide (Imcivree)](/setmelanotide-imcivree)
- [06. Online Melanotan I & II: Lab Assays](/melanotan-online-market)
- [07. Case Reports & Safety](/case-reports-and-safety)
- [08. Regulatory Records From Six Jurisdictions](/regulatory-warnings)

---

**Melanotans** is an independent educational pharmacology field report on melanocortin receptor biology, prescription medicines afamelanotide (Scenesse), bremelanotide (Vyleesi), and setmelanotide (Imcivree), and online products sold as Melanotan I and II—not a laboratory, manufacturer, clinic, pharmacy, telehealth service, or seller, and never medical advice.

- Plain-text edition: [references.md](/references.md) · Charter: [About Melanotans](/about)
- Pathway & Prescription Medicines: [Tucson Origin](/tucson-origin) · [Five Receptors](/five-receptors) · [Afamelanotide (Scenesse)](/afamelanotide-scenesse) · [Bremelanotide (Vyleesi)](/bremelanotide-vyleesi) · [Setmelanotide (Imcivree)](/setmelanotide-imcivree)
- Online Market, Safety & Charter: [Online Market & Lab Assays](/melanotan-online-market) · [Case Reports & Safety](/case-reports-and-safety) · [Regulatory Warnings](/regulatory-warnings) · [References](/references) · [About](/about) · [Contact](/contact)
